A novel system to accelerate the progression of nerve degeneration in transgenic mouse models of neuropathies

Experimental Neurology

Volumn 237, Issue 1, 2012, Pages 153-159

  Ewaleifoh, Osefame ^a   Trinh, Minh ^b   Griffin, John W ^a   Nguyen, Thien ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Washington   (United States)

Author keywords

Acrylamide; Animal model; Axonal degeneration; Charcot Marie Tooth

Indexed keywords

ACRYLAMIDE;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ELECTROPHYSIOLOGY; FLUID INTAKE; HEREDITARY MOTOR SENSORY NEUROPATHY; HIGH THROUGHPUT SCREENING; IMMUNOPATHOLOGY; IN VIVO STUDY; LATENT PERIOD; MALE; MORPHOLOGY; MOUSE; NERVE CONDUCTION; NERVE DEGENERATION; NERVE ENDING; NERVE FIBER DEGENERATION; NEUROMUSCULAR SYNAPSE; NEUROPATHY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ACRYLAMIDE; ANIMALS; AXONS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NEUROLOGIC MUTANTS; MICE, TRANSGENIC; MYELIN PROTEINS; NERVE DEGENERATION; PERIPHERAL NERVOUS SYSTEM DISEASES; RANDOM ALLOCATION;

EID: 84863829226     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.05.021     Document Type: Article

References (30)

1. Auld R.B., Bedwell S.F. Peripheral neuropathy with sympathetic overactivity from industrial contact with acrylamide. Can. Med. Assoc. J. 1967, 96:652-654.
2. Chaudhry V., Chaudhry M., Crawford T.O., Simmons-O'Brien E., Griffin J.W. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003, 60:337-340.
3. Dickerhoff R., Lindner W., Scheiber W. Severe vincristine neurotoxicity in a patient with Charcot-Marie-Tooth disease. Pediatr. Hematol. Oncol. 1988, 5:61-64.
4. Garland T.O., Patterson M.W. Six cases of acrylamide poisoning. Br. Med. J. 1967, 4:134-138.
5. Graf W.D., Chance P.F., Lensch M.W., Eng L.J., Lipe H.P., Bird T.D. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 1996, 77:1356-1362.
6. Griffin J.W., Price D.L., Drachman D.B. Impaired axonal regeneration in acrylamide intoxication. J. Neurobiol. 1977, 8:355-370.
7. Griffiths J.D., Stark R.J., Ding J.C., Cooper I.A. Vincristine neurotoxicity in Charcot-Marie-Tooth syndrome. Med. J. Aust. 1985, 143:305-306.
8. Hashimoto K., Aldridge W.N. Biochemical studies on acrylamide, a neurotoxic agent. Biochem. Pharmacol. 1970, 19:2591-2604.
9. Hayakawa K., Itoh T., Niwa H., Mutoh T., Sobue G. NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule: in vitro study of adult rat sympathetic ganglion explants. Brain Res. 1998, 794:313-319.
10. Heath J.W., Inuzuka T., Quarles R.H., Trapp B.D. Distribution of P0 protein and the myelin-associated glycoprotein in peripheral nerves from Trembler mice. J. Neurocytol. 1991, 20:439-449.
11. Henry E.W., Cowen J.S., Sidman R.L. Comparison of Trembler and Trembler-J mouse phenotypes: varying severity of peripheral hypomyelination. J. Neuropathol. Exp. Neurol. 1983, 42:688-706.
12. Ko M.H., Chen W.P., Lin-Shiau S.Y., Hsieh S.T. Age-dependent acrylamide neurotoxicity in mice: morphology, physiology, and function. Exp. Neurol. 1999, 158:37-46.
13. Krajewski K.M., Lewis R.A., Fuerst D.R., Turansky C., Hinderer S.R., Garbern J., Kamholz J., Shy M.E. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 2000, 123(Pt 7):1516-1527.
14. LoPachin R.M., Gavin T., Geohagen B.C., Das S. Neurotoxic mechanisms of electrophilic type-2 alkenes: soft soft interactions described by quantum mechanical parameters. Toxicol. Sci. 2007, 98:561-570.
15. Martino M.A., Miller E., Grendys E.C. The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer. Gynecol. Oncol. 2005, 97:710-712.
16. Meekins G.D., Emery M.J., Weiss M.D. Nerve conduction abnormalities in the trembler-j mouse: a model for Charcot-Marie-Tooth disease type 1A?. J. Peripher. Nerv. Syst. 2004, 9:177-182.
17. Miller M.S., Spencer P.S. Single doses of acrylamide reduce retrograde transport velocity. J. Neurochem. 1984, 43:1401-1408.
18. Miller M.S., Spencer P.S. The mechanisms of acrylamide axonopathy. Annu. Rev. Pharmacol. Toxicol. 1985, 25:643-666.
19. Miller M.S., Miller M.J., Burks T.F., Sipes I.G. Altered retrograde axonal transport of nerve growth factor after single and repeated doses of acrylamide in the rat. Toxicol. Appl. Pharmacol. 1983, 69:96-101.
20. Ng W.P., Cartel N., Li C., Roder J., Lozano A. Myelin from MAG-deficient mice is a strong inhibitor of neurite outgrowth. Neuroreport 1996, 7:861-864.
21. Nguyen T., Mehta N.R., Conant K., Kim K.J., Jones M., Calabresi P.A., Melli G., Hoke A., Schnaar R.L., Ming G.L., Song H., Keswani S.C., Griffin J.W. Axonal protective effects of the myelin-associated glycoprotein. J. Neurosci. 2009, 29:630-637.
22. Olek M.J., Bordeaux B., Leshner R.T. Charcot-Marie-Tooth disease type I diagnosed in a 5-year-old boy after vincristine neurotoxicity, resulting in maternal diagnosis. J. Am. Osteopath. Assoc. 1999, 99:165-167.
23. Pan B., Fromholt S.E., Hess E.J., Crawford T.O., Griffin J.W., Sheikh K.A., Schnaar R.L. Myelin-associated glycoprotein and complementary axonal ligands, gangliosides, mediate axon stability in the CNS and PNS: neuropathology and behavioral deficits in single- and double-null mice. Exp. Neurol. 2005, 195:208-217.
24. Schaumburg H.H., Wisniewski H.M., Spencer P.S. Ultrastructural studies of the dying-back process. I. Peripheral nerve terminal and axon degeneration in systemic acrylamide intoxication. J. Neuropathol. Exp. Neurol. 1974, 33:260-284.
25. Street V.A., Meekins G., Lipe H.P., Seltzer W.K., Carter G.T., Kraft G.H., Bird T.D. Charcot-Marie-Tooth neuropathy: clinical phenotypes of four novel mutations in the MPZ and Cx 32 genes. Neuromuscul. Disord. 2002, 12:643-650.
26. Tanaka Y., Hirokawa N. Mouse models of Charcot-Marie-Tooth disease. Trends Genet. 2002, 18:S39-S44.
27. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
28. Valentijn L.J., Bolhuis P.A., Zorn I., Hoogendijk J.E., van den Bosch N., Hensels G.W., Stanton V.P., Housman D.E., Fischbeck K.H., Ross D.A., et al. The peripheral myelin gene PMP-22/GAS-3 is duplicated in Charcot-Marie-Tooth disease type 1A. Nat. Genet. 1992, 1:166-170.
29. Weimer L.H., Podwall D. Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. J. Neurol. Sci. 2006, 242:47-54.
30. Yin X., Crawford T.O., Griffin J.W., Tu P., Lee V.M., Li C., Roder J., Trapp B.D. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J. Neurosci. 1998, 18:1953-1962.